Training with THOR
THOR have trained thousands of health professionals around the world. We have made a presentation at the United Nations as part of the Global Health Impact Forum, delivered a briefing for the US Congress, and even briefed the White House on photobiomodulation therapy.
There is constant innovation and progress being made in photobiomodulation. 433 academic papers were published last year, 338 up until end of August suggesting over 500 by end of 2019 so there is always something new for you to learn. The training is comprehensive, interactive and entertaining, and full of the latest evidence.
Our course covers the "first principles" of PBM, from light absorption, the cascade of intracellular/extracellular effects that follow, to physiological changes and clinical outcomes proven in randomised controlled clinical trials (RCT). Everything is explained in simple terms with illustrations and supporting video.
A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION
Markowitz SN, Devenyi RG, Munk MR, Croissant CL, Tedford SE, Rückert R, Walker MG, Patino BE, Chen L, Nido M, Tedford CE: Retina 2019 Aug 09
Age related macular degeneration is the leading cause of severe, irreversible vision loss in people over 60 years old. It is due to the deterioration of a small central portion of the retina (the macula).
The LIGHTSITE I study investigated the effectiveness and safety of photobiomodulation (PBM) treatment in people with dry age-related macular degeneration. Thirty patients were treated with the Valeda Light Delivery System three times a week for 3–4 weeks twice in a 1 year period.
Photobiomodulation-treated subjects showed a gain of 4 letters immediately after each treatment block. Almost half of them had improvement of ≥5 letters as well as other objective improvements to the condition with no adverse events reported.
In conclusion, the authors said "Photobiomodulation treatment statistically improved clinical and anatomical outcomes with more robust benefits observed in subjects with earlier stages of dry age-related macular degeneration". Repeated PBM treatments maintained benefits. These pilot findings suggest PBM is a potentially safe and effective therapy for those with dry AMD vision loss that are struggling to find a safe, well tolerated and effective therapy that helps them continue to have some sight and gain back some of their lost vision
Read the paper